Etoposide Injection, Solution
Product Images NDC 63323-104

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Etoposide (NDC 63323-104). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Fresenius Kabi Usa, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Eto05 0000 01

Chemical structure diagram of Etoposide, showing its molecular framework including multiple rings, oxygen atoms, hydroxyl groups, and methoxy groups. The diagram illustrates the spatial orientation with solid and dashed wedges indicating bond directionality.*

FDA Label Image

Eto05 0000 02

FDA Label Image

Eto05 0000 03

Label for Etoposide Injection USP, 20 mg/mL (100 mg per 5 mL) solution for intravenous injection. The label includes storage instructions (20° to 25°C), dilution requirement before intravenous infusion, and manufacturer Fresenius Kabi USA, LLC, Lake Zurich, IL. It shows a multiple dose vial with Rx only designation and a barcode with NDC 63323-104-01.*

FDA Label Image

Eto05 0000 04

Label for Etoposide Injection, USP 100 mg per 5 mL (20 mg per mL) solution for intravenous use. The label includes the Fresenius Kabi logo and mentions the vial is a 5 mL multiple dose vial. It provides sterile ingredient details, dilution instructions, storage conditions (20° to 25°C), and states the closure is not made with natural rubber latex.*

FDA Label Image

Eto05 0000 05

Etoposide Injection, USP 100 mg per 5 mL (20 mg per mL) solution for intravenous infusion. The label displays the Fresenius Kabi USA, LLC manufacturer information and includes instructions to dilute before intravenous infusion. Packaging shows a 10 x 5 mL multiple dose vial configuration with barcodes and required drug information.*

FDA Label Image

Eto05 0000 06

Etoposide Injection, USP 500 mg per 25 mL (20 mg per mL) in a 25 mL multiple dose vial. The label includes storage instructions at 20° to 25°C, specifies the product is sterile, and must be diluted before intravenous infusion. The labeler is Fresenius Kabi USA, LLC, located in Lake Zurich, IL.*

FDA Label Image

Eto05 0000 07

The image shows the unfolded carton label for Etoposide Injection, USP by Fresenius Kabi USA, LLC. The label specifies a strength of 500 mg per 25 mL (20 mg per mL) in a 25 mL multiple dose vial. It includes key storage information, dilution requirements before intravenous infusion, ingredient concentrations, and the manufacturer location in Lake Zurich, IL.*

FDA Label Image

Eto05 0000 08

Etoposide Injection, USP 20 mg/mL solution in a 50 mL multiple-dose vial. The label states 1 gram per 50 mL concentration. It is a sterile intravenous injection containing etoposide and inactive ingredients, manufactured by Fresenius Kabi USA, LLC. The label includes storage instructions and dilution requirement before intravenous infusion.*

FDA Label Image

Eto05 0000 09

Label for Etoposide Injection, USP 1 gram per 50 mL (20 mg per mL) by Fresenius Kabi USA, LLC. It is a 50 mL multiple dose vial with storage instructions (20°C to 25°C), dilution requirement before intravenous infusion, and a list of inactive ingredients. The label includes sterility and usage directions, company logo, and barcode.*

FDA Label Image

Eto05 0000 10

Etoposide Injection, USP 100 mg per 5 mL (20 mg per mL) in a 5 mL multiple dose vial. The label states it must be diluted before intravenous infusion. Contains etoposide and inactive ingredients including citric acid, benzyl alcohol, polysorbate 80, polyethylene glycol 300, and alcohol. Supplied by Fresenius Kabi USA, LLC, with storage instructions and barcodes visible.*

FDA Label Image

Eto05 0000 11

Label for Etoposide Injection, USP 100 mg per 5 mL (20 mg/mL) sterile solution in a 5 mL multiple dose vial. The label includes the active ingredient concentration, NDC 63323-104-06, manufacturer Fresenius Kabi USA, LLC, storage instructions to keep at 20° to 25°C, and a note that it must be diluted before intravenous infusion. Ingredients and packaging details are also visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.